Bausch Health Companies Inc. (formerly, Valeant Pharmaceuticals International, Inc.)
|
|||
| Mailing Address: | 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 |
Head Office Address: | 2150 St. Elzéar Blvd. West Laval, Quebec H7L 4A8 |
| Contact Name: | Daniel Yelin | Principal Regulator: | Quebec |
| Business e-mail address: | Daniel.yelin@bauschhealth.com | Short Form Prospectus Issuer: | Yes |
| Telephone Number: | 514 744-6792 | Reporting Jurisdictions: | British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland |
| Fax Number: | Stock Exchange: | TSX, NYSE | |
| Date of Formation: | Mar 29 1994 | Stock Symbol: | BHC |
| Jurisdiction Where Formed: | British Columbia | Auditor: | PricewaterhouseCoopers LLP |
| Industry Classification: | consumer products - biotechnology/pharmaceuticals | General Partner: | |
| CUSIP Number: | 91911K | Transfer Agent: | AST Trust Company (Canada) |
| Financial Year-End: | Dec 31 | Size of Issuer (Assets): | Over $1,000,000,000 |
|
